I have been excited to be a part of the STAR 3 clinical trial since becoming the Chief Medical Officer of Medtronic. The 12 month study phase results of Star 3, published in the New England Journal of Medicine, showed that there was a significant reduction in A1C in those study participants using an integrated insulin pump and CGM (SAP) compared to those using multiple daily injections (MDI). Read More >
At this year’s American Diabetes Association Scientific Sessions, new clinical data was released from the landmark STAR 3 Study which compared A1C reduction for people using an insulin pump integrated with CGM to those using multiple daily injections (MDI). We are excited to share this new data with you and hope it motivates you to keep up your good work managing diabetes. Read More >
Archive
Innovating for life.